The semaglutide market in the UK: how it grew, who it serves, and what it means for you

You've heard about semaglutide everywhere, here's the shape of the market behind that noise

A few years ago, semaglutide barely registered outside diabetes clinics. Then the STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg dose, a result that hadn't been seen with any previous licensed medicine for weight management. Demand accelerated sharply.

Novo Nordisk, semaglutide's manufacturer, struggled to keep pace. Supply constraints through 2023 and into 2024 pushed some patients toward unlicensed compounded versions and a parallel grey market in semaglutide that the MHRA has repeatedly warned against. The legitimate, licensed supply chain (through GPhC-registered pharmacies dispensing on a valid prescription) is the only route that guarantees the medicine is what it claims to be.

By 2025 the picture had shifted. Supply stabilised, a higher 7.2mg dose was approved, and the market share held by Wegovy relative to tirzepatide (Mounjaro) became a live clinical and commercial question. Both are now widely prescribed privately; both appear in NHS commissioning plans at different rates. Understanding the difference between them matters if you're considering treatment.

One thing our prescribers are asked most weeks: "Is the Wegovy I've seen advertised online the same as what I'd get through a proper pharmacy?" The short answer is that the brand, the strength, the manufacturer and the licensing are fixed, but the source matters enormously. Counterfeit pens have been seized in the UK in large quantities, and not all online sellers are operating legally.

What the market expansion actually changed for patients seeking semaglutide

The biggest practical shift has been the gap between NHS availability and private access. NICE recommended Wegovy (semaglutide 2.4mg) in technology appraisal TA875 only within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. The ethnic-background thresholds are typically 2.5 kg/m² lower. That is a narrower gate than many people expect.

Waiting lists for NHS specialist services are long in most parts of England. That reality has created a substantial private market (estimated to involve tens of thousands of UK prescriptions monthly at its 2024–25 peak) served by a mixture of registered online pharmacies, high-street chains, and, regrettably, unregistered sellers operating outside the law.

For patients, the expansion means more choice but also more noise to cut through. The timeline of Wegovy's UK launch helps explain why stock and pricing have moved around. Meanwhile, how Wegovy has been marketed in the UK is itself a regulated area: because it is a prescription-only medicine, direct advertising to the public is prohibited under the Human Medicines Regulations 2012.

What hasn't changed is the basic requirement: a legitimate prescription from a qualified prescriber, following a clinical assessment of your individual circumstances. No reputable pharmacy issues these medicines any other way.

The newest development: oral semaglutide and what it adds to the market

On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) as the first GLP-1 weight-loss medicine available in tablet form in the UK. The dosing ladder runs from 1.5mg daily up to a 25mg maintenance dose, taken first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food or other medicines. No refrigeration is needed, which addresses one of the practical barriers some patients raised about the injection.

Trial data from the OASIS 4 programme reported an average weight loss of around 13.6% over 64 weeks versus placebo; among participants who adhered fully throughout the trial, that figure was closer to 17%. These are meaningful results for a tablet, and they broaden the semaglutide market to patients who prefer not to inject.

It is worth separating this from Rybelsus, which is also oral semaglutide but at different doses (3mg, 7mg, 14mg) and licensed for type 2 diabetes, not weight management. The two products are not interchangeable. If you are exploring what semaglutide in tablet form could mean for you, more on semaglutide as a treatment explains both forms side by side.

For a fuller picture of the injection-based option before deciding, the Wegovy treatment overview covers the full dosing pathway and current eligibility in detail. If you already know where you want to buy and want to understand your options, where to buy Wegovy in the UK sets out the licensed routes. Cost is understandably a consideration too, our weight-loss treatments page shows current pricing in one place, with no hidden extras.